275 related articles for article (PubMed ID: 10613588)
41. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors.
Sørensen LK; Havemose-Poulsen A; Bendtzen K; Holmstrup P
J Periodontol; 2009 Feb; 80(2):282-9. PubMed ID: 19186969
[TBL] [Abstract][Full Text] [Related]
42. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
43. The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma.
König B; Steinbach F; Janocha B; Drynda A; Stumm M; Philipp C; Allhoff EP; König W
Anticancer Res; 1999; 19(2C):1519-24. PubMed ID: 10365136
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
45. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
Borazan A; Ustün H; Ustundag Y; Aydemir S; Bayraktaroglu T; Sert M; Yilmaz A
Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612
[TBL] [Abstract][Full Text] [Related]
46. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis.
Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G
Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510
[TBL] [Abstract][Full Text] [Related]
47. [Changes and significance of TNF, sIL-2R, IL-6, IL-4 and IFN-gamma levels in plasma from the patients with hemorrhagic fever with renal syndrome].
Liu JM; Zhu Y; Wang JP; Ouyang WM; Li Q; Zhuang R; Jin BQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):744-6. PubMed ID: 15555451
[TBL] [Abstract][Full Text] [Related]
48. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
49. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
50. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
[TBL] [Abstract][Full Text] [Related]
51. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
52. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
[TBL] [Abstract][Full Text] [Related]
53. [Soluble TNF and IL-2 receptors in patients with breast carcinoma].
Tesarová P; Kvasnicka J; Umlaufová A; Homolková J; Jirsa M; Tesar V
Cas Lek Cesk; 1998 May; 137(11):341-5. PubMed ID: 9727208
[TBL] [Abstract][Full Text] [Related]
54. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
[TBL] [Abstract][Full Text] [Related]
55. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
56. Soluble TNF and IL-2 receptors in patients with breast cancer.
Tesarová P; Kvasnicka J; Umlaufová A; Homolková H; Jirsa M; Tesar V
Med Sci Monit; 2000; 6(4):661-7. PubMed ID: 11208388
[TBL] [Abstract][Full Text] [Related]
57. [Soluble interleukin 2 receptor (sIL-2R) in patients with esophageal carcinoma].
Duan ZF
Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):17-9. PubMed ID: 8334935
[TBL] [Abstract][Full Text] [Related]
58. Soluble cytokine receptors sTNFR I and sTNFR II, receptor antagonist IL-1ra, and anti-inflammatory cytokines IL-10 and IL-13 in the pathogenesis of systemic inflammatory response syndrome in the course of burns in children.
Sikora JP; Kuzański W; Andrzejewska E
Med Sci Monit; 2009 Jan; 15(1):CR26-31. PubMed ID: 19114968
[TBL] [Abstract][Full Text] [Related]
59. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects.
Gao IK; Scholz P; Boehme MW; Norden C; Lemmel EM
Rheumatol Int; 2002 Jun; 22(2):45-51. PubMed ID: 12070674
[TBL] [Abstract][Full Text] [Related]
60. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)?
Wechsel HW; Feil G; Lahme S; Zumbragel A; Petri E; Bichler KH
Anticancer Res; 1999; 19(4A):2577-81. PubMed ID: 10470198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
